Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number

No definition available.

Name:	pfe_LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Site Contingency, Regulatory Proceedings, Disclosure Threshold

+ References

No definition available.

+ Details

Name:	pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found not to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions	1 Months Ended
	Nov. 30, 2023 Patent patent	Aug. 31, 2023 patent	Jun. 30, 2023 patent	May 31, 2023 patent Patent	Apr. 30, 2023 patent	Sep. 30, 2022 patent	Aug. 31, 2022 patent	Jul. 31, 2022 patent	Dec. 31, 2023 USD ($)
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws \| $									$ 1
Loss contingency, patents allegedly infringed and subsequently revoked \| Patent	1
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon						6
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2030 [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							2
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2033 [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							2
Mektovi [Member] \| Pfizer Versus Teva Pharmaceuticals, Inc. [Member] \| Patent Invalidity And Non Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon			3
Mektovi [Member] \| Pfizer Versus Teva Pharmaceuticals, Inc. [Member] \| Patent Invalidity And Non Infringement [Member] \| Pending Litigation [Member] \| Teva Pharmaceuticals, Inc. [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							2
Comirnaty [Member] \| ModernaTX U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed							3
Comirnaty [Member] \| Alnylam Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed \| Patent				4
Comirnaty [Member] \| ModernaTX European Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed						2	2
Comirnaty [Member] \| Arbutus and Genevant U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed					5
Comirnaty [Member] \| Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed								3
Number of patents found infringed				3
Abrysvo [Member] \| GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed	2	4